Construction method and application of prediction model for non-small cell lung cancer immune checkpoint inhibition treatment effect based on organ metastasis spectrum

Abstract

The invention relates to the field of biomedicine, in particular to a construction method and application of a prediction model for non-small cell lung cancer immune checkpoint inhibition treatment effect based on organ metastasis spectrum. The construction method comprises the following steps: evaluating and comparing the influence of different baseline transfer organs in an OAK queue on OS and PFS of patients in an attezumab group and a docetaxel group, the prediction effect of the transfer organ spectrum of different PD-L1 expression level stratification of the atezumab group and docetaxel group in OAK queue, and OS of different transfer organ types and numbers of the attezumab group and the docetaxel group in a PD-L1 positive OAK queue; establishing a scoring system METscore based on the organ transfer spectrum, performing multivariable Cox proportional risk regression, and predicting a clinical result of ICI treatment by calculating a total score of a prognosis effect and a prediction effect. Immunotherapy prediction and prognosis effects of the metastatic organ spectrum of the advanced NSCLC patient are described, clinical decisions of tumor immunotherapy patients are facilitated, and understanding of metastatic organ specificity anti-tumor immunity is improved.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a method for constructing a predictive model for the curative effect of non-small cell lung cancer immune checkpoint inhibition therapy based on an organ metastasis profile and its application. Background technique [0002] Immune checkpoint inhibitors (ICIs), represented by programmed cell death protein-1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibodies, have changed the treatment paradigm as advanced or metastatic mainstay of treatment for non-small cell lung cancer (NSCLC). Despite the success of immunotherapy relative to chemotherapy over the past decade, PD-(L)1 blockade has fallen far short of inducing durable immune responses, even in PD-L1-positive populations, there is an urgent need for reliable predictors of immunotherapy to facilitate precision medicine. [0003] The effectiveness of ICI therapy is related to the biological properties of the tumor mi...

AI Technical Summary

Problems solved by technology

However, these studies were all performed in the single-arm setting of ICI, lacking a control group of conventional treatment (e.g. chemotherapy) for comparison, resulting in the inability to distinguish between immunotherapy-specific predictions and treatment-independent prognostic effects

Furthermore, previous studies of the effect of treatment on each metastatic organ have been isolated, thus lacking a comprehensive analysis that looks at the big picture and encompasses the entire metastatic landscape; Clinical significance of outcome studies in single metastatic organs is limited

Images